+

WO1999061613A3 - Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions - Google Patents

Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions Download PDF

Info

Publication number
WO1999061613A3
WO1999061613A3 PCT/US1999/011281 US9911281W WO9961613A3 WO 1999061613 A3 WO1999061613 A3 WO 1999061613A3 US 9911281 W US9911281 W US 9911281W WO 9961613 A3 WO9961613 A3 WO 9961613A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
interference
protein interactions
mediated translation
viral ires
Prior art date
Application number
PCT/US1999/011281
Other languages
French (fr)
Other versions
WO1999061613A2 (en
Inventor
Saumitra Das
Asim Dasgupta
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Priority to AU45424/99A priority Critical patent/AU770432B2/en
Priority to JP2000550997A priority patent/JP2002516100A/en
Priority to CA002329155A priority patent/CA2329155A1/en
Priority to EP99928330A priority patent/EP1088070A2/en
Publication of WO1999061613A2 publication Critical patent/WO1999061613A2/en
Publication of WO1999061613A3 publication Critical patent/WO1999061613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides and RNA oligonucleotides and methods of use for the inhibition of translation of an mRNA, which is initiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, are disclosed. Peptides comprising the La autoantigen binding domain (LAP) are disclosed. LAP peptides alone or in combination with inhibitor RNA oligonucleotides (IRNA) may be used as antiviral agents to inhibit internal ribosome entry site (IRES) mediated viral replication.
PCT/US1999/011281 1998-05-22 1999-05-21 Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions WO1999061613A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU45424/99A AU770432B2 (en) 1998-05-22 1999-05-21 Interference with viral IRES-mediated translation by a small yeast RNA reveals critical RNA-protein interactions
JP2000550997A JP2002516100A (en) 1998-05-22 1999-05-21 Interference with viral IRES-mediated translation by yeast small RNA reveals key RNA-protein interactions
CA002329155A CA2329155A1 (en) 1998-05-22 1999-05-21 Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions
EP99928330A EP1088070A2 (en) 1998-05-22 1999-05-21 Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8652798P 1998-05-22 1998-05-22
US60/086,527 1998-05-22

Publications (2)

Publication Number Publication Date
WO1999061613A2 WO1999061613A2 (en) 1999-12-02
WO1999061613A3 true WO1999061613A3 (en) 2000-02-17

Family

ID=22199171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011281 WO1999061613A2 (en) 1998-05-22 1999-05-21 Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions

Country Status (5)

Country Link
EP (1) EP1088070A2 (en)
JP (1) JP2002516100A (en)
AU (1) AU770432B2 (en)
CA (1) CA2329155A1 (en)
WO (1) WO1999061613A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815358A1 (en) * 2000-10-17 2002-04-19 Parteurop Dev Screening for polypeptide having mutant RNA recognition site, useful for controlling viral infections, especially hepatitis C, by binding to internal ribosome entry site
US20020173475A1 (en) * 2001-04-16 2002-11-21 Asim Dasgupta Methods to inhibit viral replication
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2005080399A1 (en) 2004-02-24 2005-09-01 Japan Tobacco Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011211A1 (en) * 1994-10-11 1996-04-18 University Of California Selective inhibition of internally initiated rna translation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011211A1 (en) * 1994-10-11 1996-04-18 University Of California Selective inhibition of internally initiated rna translation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAMBERS J.C. ET AL.: "Genomic structure and amino acid sequence domains of the human La autoantigen", J. BIOL. CHEM., vol. 263, no. 34, 5 December 1988 (1988-12-05), pages 18043 - 18051, XP002125000 *
CHANG Y.-N. ET AL.: "Direct interactions between autoantigen La and human immunodeficiency virus leader RNA", J. VIROL., vol. 68, no. 11, November 1994 (1994-11-01), pages 7008 - 7020, XP002124999 *

Also Published As

Publication number Publication date
EP1088070A2 (en) 2001-04-04
WO1999061613A2 (en) 1999-12-02
AU4542499A (en) 1999-12-13
JP2002516100A (en) 2002-06-04
AU770432B2 (en) 2004-02-19
CA2329155A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
MXPA03002217A (en) Methods for delaying recurrence of herpes virus symptoms.
WO1999014346A3 (en) SENSE mRNA THERAPY
WO2004046345A3 (en) Use of hmgb fragments as anti-inflammatory agents
WO2001084148A3 (en) Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
WO2001068146A3 (en) Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
ATE276269T1 (en) SELECTIVE INHIBITION OF INTERNALLY INITIATED RNA TRANSLATION
DE69920247D1 (en) CHANGE IN DNA METHYL TRANSFERASE BY COMBINATION THERAPY
WO1999061613A3 (en) Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions
BR0008788A (en) Anti-tumor antisense sequences directed against ribonucleotide reductase r1 and r2 components
Sheng et al. Identification and characterization of a putative telomere end-binding protein from Tetrahymena thermophila
AU2004269200A8 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
WO2001093851A3 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
WO2001036460A3 (en) Methods and means for regulation of gene expression
WO1998004717A3 (en) Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner
AU6865600A (en) Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same
WO2001088124A3 (en) Method and reagent for the inhibition of erg
WO2003106625A3 (en) Hammerhead ribozymes
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
WO1997046673A3 (en) Inhibition of hiv-1 replication by antisense rna expression
AU3934000A (en) Inhibitors of endothelin-1 synthesis
DK0980526T3 (en) Inhibitors of nuclear protein / nuclear receptor interaction
EP1015630A4 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
Gross et al. Selective in situ transcription of Drosophila polytene chromosomes by Drosophila RNA polymerases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2329155

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 550997

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 45424/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999928330

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999928330

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 45424/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999928330

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载